New York University School of Medicine

Phase III Trial Compares Proton Therapy to Standard Radiation for Leptomeningeal Metastasis from Breast and Lung Cancers

- The NRG-BN014 "RADIATE-LM" trial is testing proton craniospinal radiation therapy versus standard involved-field radiation therapy for patients with leptomeningeal metastasis from breast cancer or non-small cell lung cancer. - Leptomeningeal metastasis patients typically have poor prognosis with average overall survival of 4-6 months using current standard approaches. - Proton craniospinal radiation therapy shows potential for improved survival outcomes and reduced high-grade toxicities due to its more targeted radiation delivery. - The trial activated for patient enrollment in November 2025 and aims to determine if comprehensive proton therapy improves overall survival compared to standard treatment.